Preclinical findings have been promising; for example, the addition of intra-tumoral STING agonist injection to combination ICI treatment in a syngeneic mouse model of PCa increased overall survival by 35% compared to combination ICI alone (89). Here, STING1 is linked to posterior cortical atrophy.